Wells Fargo & Company MN decreased its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 54.3% during the third quarter, Holdings Channel reports. The firm owned 6,399 shares of the biopharmaceutical company’s stock after selling 7,597 shares during the period. Wells Fargo & Company MN’s holdings in Agios Pharmaceuticals were worth $339,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of AGIO. Capital Fund Management S.A. boosted its stake in shares of Agios Pharmaceuticals by 220.0% in the third quarter. Capital Fund Management S.A. now owns 95,510 shares of the biopharmaceutical company’s stock worth $5,045,000 after buying an additional 65,663 shares during the last quarter. Beech Hill Advisors Inc. purchased a new stake in shares of Agios Pharmaceuticals during the third quarter worth $217,000. Hamilton Lane Advisors LLC purchased a new stake in shares of Agios Pharmaceuticals during the third quarter worth $1,018,000. Parametrica Management Ltd purchased a new stake in shares of Agios Pharmaceuticals during the third quarter worth $246,000. Finally, Daiwa SB Investments Ltd. purchased a new stake in shares of Agios Pharmaceuticals during the third quarter worth $435,000. 89.52% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded down 0.14% during mid-day trading on Friday, hitting $41.55. The stock had a trading volume of 380,451 shares. The firm’s market cap is $1.75 billion. Agios Pharmaceuticals, Inc. has a 12-month low of $33.50 and a 12-month high of $67.74. The company has a 50-day moving average of $51.03 and a 200-day moving average of $47.72.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.52) by $0.11. Agios Pharmaceuticals had a negative net margin of 341.56% and a negative return on equity of 53.39%. The business earned $8.98 million during the quarter, compared to analyst estimates of $7.82 million. During the same quarter in the prior year, the company earned ($1.07) earnings per share. The company’s quarterly revenue was up 63.9% on a year-over-year basis. Analysts expect that Agios Pharmaceuticals, Inc. will post ($5.23) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Daily Political and is the propert of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The correct version of this piece of content can be read at http://www.dailypolitical.com/2017/01/13/agios-pharmaceuticals-inc-agio-stake-reduced-by-wells-fargo-company-mn.html.

A number of research firms recently issued reports on AGIO. Cowen and Company reiterated a “buy” rating on shares of Agios Pharmaceuticals in a report on Monday. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Agios Pharmaceuticals in a report on Monday. Zacks Investment Research lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 3rd. Leerink Swann reiterated a “market perform” rating and issued a $45.00 target price (down from $56.00) on shares of Agios Pharmaceuticals in a report on Monday, December 19th. Finally, Canaccord Genuity set a $90.00 target price on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, December 18th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $60.24.

In related news, Director Lewis Clayton Jr. Cantley sold 2,504 shares of the stock in a transaction that occurred on Thursday, October 27th. The shares were sold at an average price of $48.94, for a total value of $122,545.76. Following the transaction, the director now directly owns 108,405 shares in the company, valued at $5,305,340.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.55% of the stock is currently owned by corporate insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

5 Day Chart for NASDAQ:AGIO

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.